Organoleptic trial of ARGAMATER 89.29% GRANULES 5.6g

Organoleptic trial of ARGAMATER 89.29% GRANULES 5.6g - Organoleptic trial of ARGAMATER 89.29% GRANULES 5.6g

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1091220098

Enrollment

Registered

2012-09-10

Start date

2012-08-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic renal failure

Interventions

Intervention type:DRUG Name of intervention:ARGAMATER GRANULES Dose form / Japanese Medical Device Nomenclature:GRANULES Route of administration / Site of application:ORAL Dose per administration:1 pa

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with chronic renal failure

Exclusion criteria

Exclusion criteria: 1 Patients with disorders of endocrine system, disorders of alimentary system, psychiatric disorders, or infection disorders. 2 Patients with swallowing disorder. 3 Patients with constipation, ileus, or gastrointestinal ulcer. 4 Patients with hyperparathyroidism or multiple myeloma. 5 Patients with a history of alcohol abuse or drug hypersensitivity. 6 Patients with drug allergies or food allergies.

Design outcomes

Primary

Measure	Time frame
Questionnaire of senses after taking medicine.	—

Countries

Japan

Contacts

Public ContactSudo Koichi

Seishukai Clinic

+81-3-5830-5654

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026